News & Events CTI Clinical Trial & Consulting Services Announces Dr. Robert Gaston has Joined as Medical Director

CTI Clinical Trial & Consulting Services Announces Dr. Robert Gaston has joined as Medical Director

January 17, 2018

FOR IMMEDIATE RELEASE [Covington, KY ~ January 10, 2018]

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization is pleased to welcome Dr. Robert Gaston as he joins the Medical Affairs team.

"We are thrilled to welcome Dr. Gaston to our team of Medical Directors" said Dr. William Aronstein, Vice President, Medical Affairs. "His experience and expertise in the treatment of critically ill patients will be a huge asset to the growing team at CTI."

Robert Gaston, MD - Medical Director
Prior to joining CTI as Medical Director, Dr. Robert (Bob) Gaston served as Vice President for Transplant Services and Director of the Comprehensive Transplant Institute at University of Alabama at Birmingham, where he held the Robert G. Luke Endowed Chair in Transplant Nephrology. ​​

 

Bob is a nephrologist with broad experience in hypertension, immunology, public policy, and solid organ transplantation.   He has been involved in clinical investigation since 1990, with research funded by industry, foundation, and government, and over 300 published articles, chapters, and abstracts.   Bob’s expertise has resulted in ongoing consultation for the National Institutes of Health (NIH), US Food and Drug Administration (FDA), several academic institutions, and industry (biotech and large pharma).  As a faculty member at the University of Alabama at Birmingham (UAB) from 1990-2017, Bob served as Interim Chief of the Division of Nephrology in 2013, and Associate Editor of the Journal of the American Society of Nephrology from 2013-17.  He was President of the American Society of Transplantation (AST) in 2011-12.


Bob earned his Bachelor of Arts from the University of Arkansas and his Doctor of Medicine form St. Louis University School of Medicine.

Subscribe to our mailing list

* indicates required